Vice President, Portfolio Chemistry
Revolution Medicines
Summary
The Vice President, Portfolio Chemistry will report to the Senior Vice President, Medicinal Chemistry and Screening Sciences, and lead Revolution Medicines' multidisciplinary Portfolio Chemistry organization, with responsibility for Medicinal Chemistry and chemistry leadership across the discovery portfolio. This executive will provide strategic and scientific leadership for the advancement of oncology programs from validated hit series through development candidate nomination.
Job description
Working at the intersection of chemistry, biology, structural sciences, computational chemistry, and translational research, the VP will be accountable for portfolio chemistry outcomes and delivery of high-quality development candidates while driving operational excellence, scientific innovation, and organizational performance across the portfolio. In this role, VP of Portfolio Chemistry will integrate modern medicinal chemistry strategies, with AI-enabled drug discovery and predictive analytics tools.
Key Responsibilities
- Partner with Research leadership to define and execute a long-term strategy for expanding the portfolio through advancement of novel small-molecule therapeutics.
- Develop and execute the chemistry strategy supporting advancement of Revolution Medicines' discovery portfolio from hit validation through development candidate nomination.
- Partner with the VP, Early Discovery Chemistry to establish clear criteria and ensure effective transitions from hit identification/validation into portfolio medicinal chemistry.
- Drive integration of chemistry with computational chemistry, digital drug discovery, AI/ML technologies, and data science capabilities across discovery workflows.
- Lead organizational planning, internal and external resource allocation (CRO management), talent strategy, and capability development across multiple functions.
- Partner with Research Leadership to prioritize resources and maximize portfolio value.
- Drive alignment across Research functions to support a dynamic portfolio of discovery and development-stage programs.
- Partner with Research Leadership to translate portfolio strategy into differentiated chemistry programs and ensure effective advancement of the highest-value opportunities.
- Establish and maintain exceptional chemistry project leadership across the portfolio, developing capable project leaders.
- Champion predictive analytics, AI/ML methodologies, and computational approaches that increase throughput and accelerate DMTA cycles.
- Manage a high-performing group, sustain productivity through strategic hiring, mentoring, and support for individual career growth.
- Be accountable for an annual budget.
- Position the MedChem function as a bridge across Research, enabling bench-to-bedside insights.
- Serve as a visible leader representing Revolution Medicines’ scientific excellence internally and externally.
Required Skills, Experience and Education
- Ph.D. in Organic Chemistry.
- Minimum 16+ years of industrial drug discovery experience with extensive medicinal chemistry leadership.
- Demonstrated success advancing multiple programs from hit validation through development candidate nomination and ideally IND-enabling studies.
- Proven leadership of multidisciplinary chemistry organizations supporting multiple concurrent discovery programs.
- Deep expertise in medicinal chemistry, structure-based drug design, optimization strategies, and candidate selection.
- Experience integrating computational chemistry, AI/ML technologies, and digital drug discovery into medicinal chemistry workflows.
- Strong experience managing external collaborations, CROs, and strategic partnerships.
- Outstanding leadership, communication, and organizational development skills.
- Demonstrated ability to build, lead, and foster a collaborative culture on interdisciplinary teams.
Preferred Skills
- Experience in oncology drug discovery.
- Experience of successful IND filings and clinical candidate delivery.
- Record of scientific publications, patents, and invited presentations.
- Experience with alternative modality, ex. molecular glue and ADC drug discovery.
Requirements
- Ph.D. in Organic Chemistry
- Minimum 16+ years of industrial drug discovery experience with extensive medicinal chemistry leadership
- Demonstrated success advancing multiple programs from hit validation through development candidate nomination and ideally IND-enabling studies
- Proven leadership of multidisciplinary chemistry organizations supporting multiple concurrent discovery programs
- Deep expertise in medicinal chemistry, structure-based drug design, optimization strategies, and candidate selection
- Experience integrating computational chemistry, AI/ML technologies, and digital drug discovery into medicinal chemistry workflows
- Strong experience managing external collaborations, CROs, and strategic partnerships
- Outstanding leadership, communication, and organizational development skills
- Demonstrated ability to build, lead, and foster a collaborative culture on interdisciplinary teams
- Experience in oncology drug discovery
- Experience of successful IND filings and clinical candidate delivery
- Record of scientific publications, patents, and invited presentations
- Experience with alternative modality, ex. molecular glue and ADC drug discovery
Benefits
- Competitive cash compensation
- Robust equity awards
- Strong benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.